Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neoleukin Therapeutics, Inc. - Common Stock (NQ:NLTX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 18, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neoleukin Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
From Neoleukin Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Why Orchard Therapeutics Shares Are Trading Higher By Around 95%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Neoleukin Pauses Development Of NL-201, Cuts 40% Of Employee Strength
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are rising and falling on Thursday as we check out all of the latest news worth knowing about this morning! 
Via InvestorPlace
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
From Neoleukin Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
NEOLEUKIN THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sculptor Capital Management Inc. (NYSE – SCU), Neoleukin Therapeutics, Inc. (Nasdaq - NLTX), Pardes Bioscience, Inc. (Nasdaq – PRDS), Great Ajax Corp. (NYSE – AJX)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Neoleukin Therapeutics, Inc. (Nasdaq - NLTX), Pardes Bioscience, Inc. (Nasdaq – PRDS), Kaleyra, Inc. (NYSE – KLR), Great Ajax Corp. (NYSE – AJX)
From Brodsky & Smith LLC
Via GlobeNewswire
Neoleukin Therapeutics To Merge With Neurogene: Creates Biotech Firm Focused On Genetic Medicines For Neurological Diseases
Privately-held Neurogene Inc has agreed to merge with Neoleukin Therapeutics Inc (NASDAQ: NLTX) in  
Via Benzinga
NLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Neurogene and Neoleukin Announce Definitive Merger Agreement
From Neoleukin Therapeutics, Inc.
Via GlobeNewswire
US Stocks Turn Lower; S&P 500 Down 1%
U.S. stocks turned lower toward the end of trading, with the Dow Jones dropping around 300 points on Thursday. The Dow traded down 0.88% to 32,510.83 while the NASDAQ fell 1.34% to 11,421.06. The S&P... 
Via Benzinga
Why JD.com Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
US Stocks Pare Gains; BJ's Wholesale Club Earnings Top Views
U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining 20 points on Thursday. The Dow traded up 0.02% to 32,804.33 while the NASDAQ rose 0.17% to 11,595.87. The... 
Via Benzinga
Neoleukin Therapeutics Seeks Strategic Alternatives, To Layoff More In Round 2 Within 6 Months
Neoleukin Therapeutics Inc (NASDAQ: NLTX) has engaged SVB Securities to assist in reviewing strategic alternatives.  
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Why Cassava Sciences Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for another breakdown of the biggest pre-market stock movers traders will want to know about on Thursday morning! 
Via InvestorPlace
Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition
From Neoleukin Therapeutics, Inc.
Via GlobeNewswire
Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting
Targeted, precision-tuned agonist of IL-2 receptor selectively expands regulatory T cells 
From Neoleukin Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 70 companies set new 52-week lows. 
Via Benzinga
5 Analysts Have This to Say About Neoleukin Therapeutics
Analysts have provided the following ratings for Neoleukin Therapeutics (NASDAQ:NLTX) within the last quarter: 
Via Benzinga
Pinterest To $23? Plus This Analyst Slashes PT On Neoleukin Therapeutics By More Than 90%
Rosenblatt raised the price target on Pinterest, Inc. (NYSE: PINS) from $21 to $23. Rosenblatt analyst Barton Crockett maintained a Neutral rating on the stock. Pinterest shares rose 2% to $24.91 in... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2022
Upgrades 
Via Benzinga
Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%
  Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics shares fell 3% to close at $53.30 on Monday. 
Via Benzinga
Why Fast Radius Shares Plunged Around 48%; Here Are 103 Biggest Movers From Yesterday
Gainers Satixfy Communications Ltd. (NYSE: SATX) shares gained 140.7% to settle at $31.80 on Tuesday. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS